Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 23 clinical trials
featured
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)

metastatic cholangiocarcinoma with FGFR2 rearrangement.  

metastatic cancer
cancer
FGFR2
primary cancer
  • 154 views
  • 14 Dec, 2020
  • 155 locations
featured
  • 1672 views
  • 23 Nov, 2020
  • 25 locations
Biomoleculars Markers of Sensitivity to Pre- and Post-operative Chemotherapy of Gastric and Cardia Adenocarcinomas: a Pilot Study

, Her2, FGFR2) and mutations (p53 ras) in frequently deregulated genes in gastric cancers. To characterize the level of expression of predictive candidate markers (Np73, TAp73, HDAC4, mir140

  • 0 views
  • 25 Jan, 2021
  • 1 location
Derazantinib in Subjects With FGFR2 Gene Fusion- Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma

inoperable or advanced intrahepatic cholangiocarcinoma (iCCA) whose tumors harbor FGFR2 gene fusions (by FISH performed by the central laboratory) or FGFR2 gene mutations or amplifications (based on NGS

liver metastases
cancer
FGFR2
cholangiocarcinoma
measurable disease
  • 190 views
  • 15 Jul, 2021
  • 52 locations
Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

Infigratinib is an oral drug which selectively binds to fibroblast growth factor receptor (FGFR) 2 and is being developed to treat participants with FGFR2 mutated cholangiocarcinoma. The purpose

  • 20 views
  • 25 Jul, 2021
  • 122 locations
A Phase II Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma

This is a multi-center, open label, single arm phase II study evaluating BGJ398 anti-tumor activity in advanced or metastatic cholangiocarcinoma patients with Fibroblast Growth Factor receptor (FGFR) genetic alterations.

  • 109 views
  • 23 Jul, 2021
  • 36 locations
A Study of TAS-120 in Patients With Metastatic Breast Cancer

The purpose of this open-label, nonrandomized, Phase 2 study is to evaluate the efficacy and safety of TAS-120 and TAS-120 + fulvestrant in patients with locally advanced/metastatic breast cancer harboring FGFR gene amplifications.

fulvestrant
breast cancer
endocrine therapy
neutrophil count
platelet count
  • 17 views
  • 25 Jan, 2021
  • 23 locations
  • 51 views
  • 01 Apr, 2021
  • 312 locations
Derazantinib Alone or in Combination With Paclitaxel Ramucirumab or Atezolizumab in Gastric Adenocarcinoma

adenocarcinoma of the stomach or gastro-esophageal junction harboring FGFR2 genetic aberrations (GA).

  • 0 views
  • 15 Jul, 2021
  • 70 locations